Access turnkey CRO solutions specifically engineered for Austrian life science institutions, nutraceutical developers, and botanical innovators seeking EMA/BASG market authorization.
Navigating the intersection of rigorous Austrian Federal Office for Safety in Health Care (BASG) requirements, high Alpine phytomedicine demand, and rising operational clinical costs.
Austria’s biotech ecosystems, centered around Vienna BioCenter and the Tyrolean health innovation hubs, excel in basic biomedical research. However, clinical pipeline developers frequently face intense domestic resource bottlenecks, lengthy ethics committee backlogs, and disproportionately high per-patient recruitment overheads for clinical validation.
Under the European Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC) and national regulations enforced by the AGES (Austrian Agency for Health and Food Safety), bringing botanical products to pharmacy-grade standing demands systematic pharmacological characterization and validated human clinical data that traditional suppliers often fail to provide.
MedGence bridges this gap by acting as an end-to-end clinical trial and manufacturing bridgehead. By standardizing plant-derived actives to Ph. Eur. monographs and executing multi-center Phase I through Phase IV trials, we empower Austrian pharmaceutical sponsors to secure high-tier commercial differentiation without exorbitant domestic trial overheads.
The pharmaceutical sector is experiencing an unprecedented transition toward standardized botanical formulations and multi-omics driven clinical trial protocols.
Traditional herbal trials have long suffered from batch variability, uncontrolled phytochemical composition, and unstandardized extraction techniques. Global regulatory authorities—from the EMA in Europe to the FDA in North America—now require rigorous chromatographic fingerprinting (HPLC, HPTLC, GC-MS) before human clinical trial protocol approvals can be authorized.
Contract research organizations must align with ICH Harmonised Tripartite Guideline for Good Clinical Practice (E6(R2)). Developing high-fidelity protocols that combine biomarker quantification, pharmacokinetic profiling, and double-blind placebo control is mandatory to substantiate high-value therapeutic and metabolic health claims internationally.
Decentralized Clinical Trials (DCT) and continuous biological telemetry allow real-time monitoring of patient endpoints. Our clinical data architectures interface seamlessly with clinical trial management systems (CTMS), offering sponsors complete transparency from electronic data capture (EDC) to bio-statistical signoff.
Every clinical stage executed by MedGence is constructed to satisfy both Austrian domestic mandates (AMG, AGES) and pan-European harmonized directives.
| Regulatory Body / Framework | Compliance Requirement | MedGence Operational Safeguard | Applicable Austrian Scope |
|---|---|---|---|
| AGES / BASG (Austria) | Clinical Trial Authorization & Pharmacovigilance reporting (AMG) | Full GCP study dossier drafting, safety monitoring committee setup, and e-reporting integration. | Phytopharmaceutical investigational medicinal products (IMPs) |
| EU Regulation 536/2014 | Clinical Trials Information System (CTIS) portal submission | Part I & Part II CTIS dossier generation including biological IMPDs and Investigator’s Brochures (IB). | Cross-border clinical research targeting EU commercial markets |
| European Pharmacopoeia (Ph. Eur.) | Standardized monographs for botanical purity, pesticide limits, and heavy metals | Validated HPLC/HPTLC fingerprinting, GC-MS impurity screening, and batch verification under GMP. | Raw extracts, botanical active substances, and finished formulations |
| EFSA Guidance (Article 13.5 & 14) | Substantiation of health claims using randomized controlled human trials | Double-blind, randomized, placebo-controlled human dietary supplement clinical testing frameworks. | Functional food, nutraceutical capsules, and medical food lines |
Case-tailored clinical validation tracks matching the specific needs of Austrian healthcare developers, specialty pharma brands, and pharmacy laboratories.
Austria’s aging demographic demands proven preventive metabolic support. We architect Phase II and human dietary intervention studies for plant-derived polyphenols, berberine analogs, and anthocyanin fractions to evaluate fasting blood glucose, HbA1c reduction, and lipid markers under strict blinding.
Collaborating with Central European wellness and functional brain-health brands, we perform placebo-controlled cognitive battery assessments, validated mood scales, and neuro-inflammatory biomarker tracking for adaptogenic compounds, nootropics, and standardized herbal extract combinations.
Addressing Austria’s active alpine sports enthusiasts and arthritic patient groups, we implement multi-endpoint musculoskeletal clinical trials utilizing WOMAC indices, VAS pain tracking, and serum CRP levels for novel botanical anti-inflammatory extracts and topical emulsions.
How we take a botanical candidate from initial phytochemical isolation to verified clinical data and commercial CDMO batch manufacturing.
High-resolution screening of botanical active compounds using HPLC-DAD-MS/MS and chemical fingerprinting. Selection of ideal plant parts, seasonal harvesting windows, and geographic origins to maximize active substance content.
Rigorous in vitro cell-based mechanistic discovery alongside GLP-compliant toxicological studies (LD50, acute, sub-chronic, Ames genotoxicity) to establish safety profiles required for human research ethics applications.
Full-scale clinical study protocol development aligned with EU-CTR and Austrian BASG guidelines. Management of institutional review boards (IRBs), patient recruitment, monitoring, data audit trails, and bio-statistical evaluation.
Seamless transfer of research parameters to our GMP production lines. Scaled manufacturing of standardized botanical actives and finished dosage forms (capsules, tablets, softgels, oral liquids) with batch-to-batch analytical verification.
Key insights for scientific directors, procurement heads, and regulatory affairs executives evaluating MedGence as an ODM clinical research partner.
Explore our complete suite of research capabilities, analytical protocols, and preclinical-to-clinical platforms optimized for Austrian healthcare partnerships.
Whether you require exploratory in vitro assays, GCP-validated human trials, or pilot-to-commercial contract manufacturing for botanical active ingredients, our scientific team is ready to assist.
